

What is claimed is:

1. A method of treating sexual dysfunction which comprises administering by inhalation an effective amount of an inhibitor of cGMP PDE 5 to a subject in need of such treatment.
2. A method according to claim 1, in which said inhibitor is a pyrazolopyrimidinone or an aminoquinazoline derivative.
3. A method according to claim 2, in which said inhibitor is a pyrazolopyrimidinone as disclosed in published International Patent Application No. WO94/28902, WO96/16657 or WO98/49166 or published European Patent Application No EP-A-0636626, a 4-aminoquinazoline derivative as disclosed in US Patent No. 5436233, an arylpyrazolopyrimidinone as disclosed in published International Patent Application No. WO96/28448 or a 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-one as disclosed in US Patent 5294612.
4. A method according to claim 3, in which said inhibitor is 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one or 1-cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin-4-one.
5. A method according to claim 1, in which the inhalable form of said medicament is an atomisable composition or a finely divided particulate form.
6. A method according to claim 2, in which the inhalable form of said medicament is an atomisable composition or a finely divided particulate form.
7. A method according to claim 3, in which the inhalable form of said medicament is an atomisable composition or a finely divided particulate form.
8. A method according to claim 5, in which said inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.

090827-06404

9. A method according to claim 6, in which said inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.
10. A method according to claim 7, in which said inhalable form is an aerosol comprising said inhibitor in solution or dispersion in a propellant or a nebulizable composition comprising a dispersion of said inhibitor in an aqueous or aqueous/organic medium.
11. A method according to claim 5, in which said inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.
12. A method according to claim 6, in which said inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.
13. A method according to claim 7, in which said inhalable form is a finely divided particulate form comprising said inhibitor in finely divided particulate form, optionally together with a particulate carrier.
14. A medicament comprising a cGMP PDE 5 inhibitor as disclosed in WO94/28902, WO96/16657, WO98/49166, EP-A-0636626 or US5436233 in inhalable form.
15. A medicament according to claim 14, in which the inhibitor is 5-[2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-phenylmethylamino-6-chloro-2-(1-imidazolyl)quinazoline, 4-phenylmethylamino-6-chloro-2-(3-pyridyl)quinazoline, or 1,3-dimethyl-6-(2-propoxy-5-methanesulfonylamidophenyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one.
16. A medicament according to claim 14, in which the inhalable form is an atomisable composition or a finely divided particulate form.

- add B²